We are live on ! Find out more
GLUE icon

Monte Rosa Therapeutics
GLUE

48 hedge funds and large institutions have $705M invested in Monte Rosa Therapeutics in 2021 Q2 according to their latest regulatory filings, with 48 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

72.14% more ownership

Funds ownership: 0% → 72.14% (+72%)

Holders
48
Holders Change
+48
Holders Change %
–
% of All Funds
0.84%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.05%
New
48
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
NMC
NEA Management Company
Maryland
+$157M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$87.8M
3
ACA
Avoro Capital Advisors
New York
+$67.4M
4
CAM
Cormorant Asset Management
Massachusetts
+$65.1M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$55.8M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
NMC
1
NEA Management Company
Maryland
$175M +$157M +7,703,205 New
Fidelity Investments
2
Fidelity Investments
Massachusetts
$93.5M +$87.8M +4,312,259 New
CAM
3
Cormorant Asset Management
Massachusetts
$69.5M +$65.1M +3,193,973 New
ACA
4
Avoro Capital Advisors
New York
$62.2M +$67.4M +3,311,434 New
T. Rowe Price Associates
5
T. Rowe Price Associates
Maryland
$61.3M +$55.8M +2,737,654 New
BlackRock
6
BlackRock
New York
$35.2M +$31.6M +1,549,885 New
ACM
7
Aisling Capital Management
New York
$33.4M +$30M +1,472,331 New
AI
8
Alphabet Inc
California
$33.2M +$29.8M +1,464,015 New
RI
9
RTW Investments
New York
$25.2M +$24.7M +1,214,572 New
CC
10
Casdin Capital
New York
$21.8M +$19.6M +960,883 New
DM
11
Deerfield Management
New York
$7.95M +$7.13M +350,000 New
O
12
OrbiMed
New York
$7.95M +$7.13M +350,000 New
APM
13
Avidity Partners Management
Texas
$6.81M +$6.11M +300,000 New
Jennison Associates
14
Jennison Associates
New York
$6.81M +$6.11M +300,000 New
LGM
15
Logos Global Management
California
$6.81M +$6.11M +300,000 New
OCA
16
Octagon Capital Advisors
New York
$5.4M +$4.85M +238,045 New
Millennium Management
17
Millennium Management
New York
$5.34M +$4.79M +235,102 New
WP
18
Woodline Partners
California
$4.72M +$4.24M +208,068 New
SCM
19
Suvretta Capital Management
New York
$3.4M +$3.06M +150,000 New
AllianceBernstein
20
AllianceBernstein
Tennessee
$3.16M +$2.83M +139,095 New
SAM
21
Sectoral Asset Management
Quebec, Canada
$2.94M +$2.64M +129,633 New
MIM
22
Monashee Investment Management
Massachusetts
$2.72M +$2.44M +120,000 New
RCM
23
Ratan Capital Management
Florida
$2.72M +$2.44M +120,000 New
Goldman Sachs
24
Goldman Sachs
New York
$2.46M +$2.21M +108,500 New
VOYA Investment Management
25
VOYA Investment Management
Georgia
$2.36M +$2.12M +104,177 New
1
2

GLUE Hedge Fund Activity: Q2 2021 in Review

48 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Monte Rosa Therapeutics (GLUE) for Q2 2021, worth a combined $705M.

Buyers outnumbered sellers: 48 funds opened new GLUE positions and 0 closed out — a net gain of 48 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was NEA Management Company, opening a new position worth an estimated $157M.

  • 48 institutional investors held Monte Rosa Therapeutics (GLUE) as of Q2 2021, up from 0 in Q1 2021.
  • Funds reported $705M of Monte Rosa Therapeutics stock for Q2 2021.
  • 48 funds opened new Monte Rosa Therapeutics positions in Q2 2021 and 0 closed out, a net change of +48 holders.
  • The largest Monte Rosa Therapeutics buyer in Q2 2021 was NEA Management Company, an estimated $157M added.

Based on aggregated 13F filings for Q2 2021.